Activation of S1P2 is protective against cisplatin-induced peripheral neuropathy

Brenda Wan Shing Lam; Ping Xiang; Boya Peng; Ling Jun Joshua Soon; Amelia Ting Yu Yam; Claudine Ming Hui Lim; Yu Zheng; Long N. Nguyen; Deron R. Herr; Minh T. N. Le

doi:10.1111/cpr.13549

Cell Proliferation ›› 2024, Vol. 57 ›› Issue (2) : e13549 DOI: 10.1111/cpr.13549

LETTER TO THE EDITOR

Activation of S1P₂ is protective against cisplatin-induced peripheral neuropathy

Brenda Wan Shing Lam ¹^,²^,³
, Ping Xiang ¹
, Boya Peng ¹^,²^,³
, Ling Jun Joshua Soon ⁴
, Amelia Ting Yu Yam ¹
, Claudine Ming Hui Lim ¹^,²^,³
, Yu Zheng ¹^,²^,³
, Long N. Nguyen ⁵^,⁶^,⁷^,⁸
, Deron R. Herr ¹^,⁹^,^†
, Minh T. N. Le ¹^,²^,³^,⁸^,^†

Author information +

¹. Department of Pharmacology and Institute for Digital Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

². Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

³. Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore

⁴. Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

⁵. Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

⁶. Singapore Lipidomics Incubator (SLING), Life Sciences Institute, National University of Singapore, Singapore, Singapore

⁷. Cardiovascular Disease Research (CVD) Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

⁸. Immunology Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

⁹. Translational Neuroscience Initiative, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA

dherr@sbpdiscovery.org

phcltnm@nus.edu.sg

Show less

History +

PDF

Cite this article

Download citation ▾

Brenda Wan Shing Lam, Ping Xiang, Boya Peng, Ling Jun Joshua Soon, Amelia Ting Yu Yam, Claudine Ming Hui Lim, Yu Zheng, Long N. Nguyen, Deron R. Herr, Minh T. N. Le. Activation of S1P₂ is protective against cisplatin-induced peripheral neuropathy. Cell Proliferation, 2024, 57(2): e13549 DOI:10.1111/cpr.13549

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Speck RM, DeMichele A, Farrar JT, et al. Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients. Support Care Cancer. 2012;20(10):2433-2439.

[2]	Hughes RAC. Peripheral neuropathy. BMJ. 2002;324(7335):466-469.

[3]	Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461-2470.

[4]	Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F. An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Exp Neurol. 2003;182(1):12-20.

[5]	Fornaro M, Sharthiya H, Tiwari V. Adult mouse DRG explant and dissociated cell models to investigate neuroplasticity and responses to environmental insults including viral infection. J Vis Exp. 2018;133:56757.

[6]	Canta A, Pozzi E, Carozzi VA. Mitochondrial dysfunction in chemotherapy-induced peripheral neuropathy (CIPN). Toxics. 2015;3(2):198-223.

[7]	Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci. 2019;20(6):1451.

[8]	Eldridge S, Guo L, Hamre J. A comparative review of chemotherapy-induced peripheral neuropathy in in vivo and in vitro models. Toxicol Pathol. 2020;48(1):190-201.

[9]	Puri BK. Calcium signaling and gene expression. Adv Exp Med Biol. 2020;1131:537-545.

[10]	Brini M, Calì T, Ottolini D, Carafoli E. Neuronal calcium signaling: function and dysfunction. Cell Mol Life Sci. 2014;71(15):2787-2814.

[11]	Kawamoto EM, Vivar C, Camandola S. Physiology and pathology of calcium signaling in the brain. Front Pharmacol. 2012;3:61.

[12]	Fukuda Y, Li Y, Segal RA. A mechanistic understanding of axon degeneration in chemotherapy-induced peripheral neuropathy. Front Neurosci. 2017;11:481.

[13]	Wang W, Xiang P, Chew WS, et al. Activation of sphingosine 1-phosphate receptor 2 attenuates chemotherapy-induced neuropathy. J Biol Chem. 2020;295(4):1143-1152.

[14]	Cankara FN, Günaydın C, Çelik ZB, et al. Agomelatine confers neuroprotection against cisplatin-induced hippocampal neurotoxicity. Metab Brain Dis. 2021;36(2):339-349.

[15]	Ta LE, Espeset L, Podratz J, Windebank AJ. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology. 2006;27(6):992-1002.

[16]	English K, Shepherd A, Uzor NE, Trinh R, Kavelaars A, Heijnen CJ. Astrocytes rescue neuronal health after cisplatin treatment through mitochondrial transfer. Acta Neuropathol Commun. 2020;8(1):36.

[17]	Sheth S, Mukherjea D, Rybak LP, Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and otoprotection. Front Cell Neurosci. 2017;11:338.

[18]	Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119(1):7-35.

[19]	Hanani M. How is peripheral injury signaled to satellite glial cells in sensory ganglia? Cell. 2022;11(3):512.

[20]	Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron. 2006;52(1):77-92.

[21]	Kallenborn-Gerhardt W, Schröder K, Schmidtko A. NADPH oxidases in pain processing. Antioxidants (Basel). 2022;11(6):1162.

[22]	More SV, Koppula S, Kim IS, Kumar H, Kim BW, Choi DK. The role of bioactive compounds on the promotion of neurite outgrowth. Molecules. 2012;17(6):6728-6753.

[23]	He Z, Guo JL, McBride JD, et al. Amyloid-β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat Med. 2018;24(1):29-38.

[24]	Mehra S, Sahay S, Maji SK. α-Synuclein misfolding and aggregation: implications in Parkinson's disease pathogenesis. Biochim Biophys Acta Proteins Proteom. 2019;1867(10):890-908.

[25]	Uchida Y, Gomi F. The role of calsyntenin-3 in dystrophic neurite formation in Alzheimer's disease brain. Geriatr Gerontol Int. 2016;16(Suppl 1):43-50.

[26]	Xiong M, Zou L, Meng L, et al. A γ-adducin cleavage fragment induces neurite deficits and synaptic dysfunction in Alzheimer's disease. Prog Neurobiol. 2021;203:102074.

[27]	Hadimani MB, Purohit MK, Vanampally C, et al. Guaifenesin derivatives promote neurite outgrowth and protect diabetic mice from neuropathy. J Med Chem. 2013;56(12):5071-5078.

[28]	Kawashiri T, Shimizu S, Shigematsu N, Kobayashi D, Shimazoe T. Donepezil ameliorates oxaliplatin-induced peripheral neuropathy via a neuroprotective effect. J Pharmacol Sci. 2019;140(3):291-294.

[29]	Bucan V, Vaslaitis D, Peck CT, Strauß S, Vogt PM, Radtke C. Effect of exosomes from rat adipose-derived mesenchymal stem cells on neurite outgrowth and sciatic nerve regeneration after crush injury. Mol Neurobiol. 2019;56(3):1812-1824.

[30]	Fujita A, Hattori Y, Takeuchi T, Kamata Y, Hata F. NGF induces neurite outgrowth via a decrease in phosphorylation of myosin light chain in PC12 cells. Neuroreport. 2001;12(16):3599-3602.

[31]	Minase T, Ishima T, Itoh K, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by the ROCK inhibitor Y-27632: a possible role of IP₃ receptors. Eur J Pharmacol. 2010;648(1–3):67-73.

[32]	Roloff F, Scheiblich H, Dewitz C, Dempewolf S, Stern M, Bicker G. Enhanced neurite outgrowth of human model (NT2) neurons by small-molecule inhibitors of Rho/ROCK signaling. PLoS One. 2015;10(2):e0118536.

[33]	Munnamalai V, Weaver CJ, Weisheit CE, et al. Bidirectional interactions between NOX2-type NADPH oxidase and the F-actin cytoskeleton in neuronal growth cones. J Neurochem. 2014;130(4):526-540.

[34]	Herr DR, Reolo MJY, Peh YX, et al. Sphingosine 1-phosphate receptor 2 (S1P2) attenuates reactive oxygen species formation and inhibits cell death: implications for otoprotective therapy. Sci Rep. 2016;6:24541.